Sugi Predict

Sugi Predict / Targets / KDM6A

KDM6A

Lysine-specific demethylase 6A · O15550 · KDM6A on Sugi Atlas →

3,329 patent compounds predicted against KDM6A, 2,382 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2721745 SCHEMBL2721745 0.73 5/20
SCHEMBL2721747 SCHEMBL2721747 0.72 5/20
SCHEMBL2721826 SCHEMBL2721826 0.67 5/20
SCHEMBL2722008 SCHEMBL2722008 0.59 5/20
SCHEMBL2722313 SCHEMBL2722313 0.58 5/20
SCHEMBL3162586 SCHEMBL3162586 0.51 5/20
SCHEMBL3162597 SCHEMBL3162597 0.51 5/20
SCHEMBL2722871 SCHEMBL2722871 0.50 5/20
SCHEMBL2723357 SCHEMBL2723357 0.56 4/20
SCHEMBL2723353 SCHEMBL2723353 0.64 3/20
SCHEMBL3175765 SCHEMBL3175765 0.44 3/20
SCHEMBL3172228 SCHEMBL3172228 0.43 3/20
SCHEMBL4697774 SCHEMBL4697774 0.55 2/20
SCHEMBL1727683 SCHEMBL1727683 0.48 2/20
SCHEMBL3163116 SCHEMBL3163116 0.44 2/20
SCHEMBL3161868 SCHEMBL3161868 0.43 2/20
SCHEMBL3171007 SCHEMBL3171007 0.43 2/20
SCHEMBL3170848 SCHEMBL3170848 0.42 2/20
SCHEMBL3175541 SCHEMBL3175541 0.38 2/20
Deferiprone Deferiprone (SCHEMBL94474) 1.00 1/20

Clinical trials — most relevant to KDM6A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
ARID1A and/or KDM6A Mutation and CXCL13 Expression PHASE2ACTIVE_NOT_RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment PHASE1/PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer PHASE1SUSPENDED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours PHASE1COMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
The Danish TURNER Cryopreservation Study nanRECRUITING
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
MIF Involvement in AML nanACTIVE_NOT_RECRUITING
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
The Crosstalk Between the Epigenome and Mitochondria in SCI nanNOT_YET_RECRUITING
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
Prevalence and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia nanUNKNOWN
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
Exploiting Epigenome Editing in Kabuki Syndrome: a New Route Towards Gene Therapy for Rare Genetic Disorders nanCOMPLETED
Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KDM6A binder may also engage these)

ProteinNameSimilarity
O70546 — 1.000 O70546 →
O14607 — 1.000 O14607 →
Q6B4Z3 — 0.996 Q6B4Z3 →
Q8K2L8 — 0.992 Q8K2L8 →
P79457 — 0.990 P79457 →
Q8HWS3 — 0.990 Q8HWS3 →
Q62415 — 0.988 Q62415 →
A0M8T5 — 0.987 A0M8T5 →
Q00PJ1 — 0.987 Q00PJ1 →
E1BZ85 — 0.987 E1BZ85 →
D2HNW6 — 0.987 D2HNW6 →
Q09YK4 — 0.986 Q09YK4 →
Q07E15 — 0.986 Q07E15 →
Q5XJV7 — 0.986 Q5XJV7 →
Q9H694 — 0.986 Q9H694 →
KAT2B Histone acetyltransferase KAT2B 0.986 landscape →
Q2IBA2 — 0.986 Q2IBA2 →
Q6EE22 — 0.986 Q6EE22 →
Q9Y4F3 — 0.986 Q9Y4F3 →
Q9Z136 — 0.986 Q9Z136 →
TRIM24 Transcription intermediary factor 1-alpha 0.986 landscape →
Q62315 — 0.985 Q62315 →
Q07DV1 — 0.985 Q07DV1 →
Q09YG9 — 0.985 Q09YG9 →
Q09YI1 — 0.985 Q09YI1 →
B9EJA2 — 0.985 B9EJA2 →
B2GUN4 — 0.985 B2GUN4 →
Q2QLB3 — 0.985 Q2QLB3 →
Q09YM8 — 0.985 Q09YM8 →
A0AVK6 — 0.985 A0AVK6 →